Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000654919 | SCV000776825 | likely benign | RASopathy | 2023-09-22 | criteria provided, single submitter | clinical testing | |
St. |
RCV002254706 | SCV002525964 | uncertain significance | CBL-related disorder | 2022-02-03 | criteria provided, single submitter | clinical testing | The CBL NM_005188.3 (c.1552A>G; p.Thr518Ala) missense change has a maximum subpopulation frequency of 0.012% in gnomAD v2.1.1 ( https://gnomad.broadinstitute.org/variant/11-119155799-A-G ). Seven of seven in silico tools predict a benign effect of this variant on protein function (BP4), but to our knowledge these predictions have not been confirmed by functional assays. To our knowledge, this variant has not been reported in individuals with Noonan syndrome-like disorders. In summary, this variant meets criteria to be classified as of uncertain significance based on the ACMG/AMP criteria: BP4 |
Ambry Genetics | RCV004025943 | SCV005022967 | uncertain significance | Cardiovascular phenotype | 2023-12-25 | criteria provided, single submitter | clinical testing | The p.T518A variant (also known as c.1552A>G), located in coding exon 10 of the CBL gene, results from an A to G substitution at nucleotide position 1552. The threonine at codon 518 is replaced by alanine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |